BridgeMD
Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in patients with acute coronary syndrome (TACSI trial)
EU CTIS ID: 2023-508551-40-00
What this study is testing
To assess whether dual antiplatelet therapy (DAPT) with ticagrelor and ASA compared to ASA alone improves 12 months outcome defined as major adverse cardiovascular events (MACE) after isolated Coronary Artery Bypass Grafting (CABG) in Acute Coronary Syndrome (ACS) patients.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Written informed consent
- Age ≥18 years
- Has undergone first time isolated CABG due to an episode of acute coronary syndrome (STEMI, NSTEMI, unstable angina) within 6 weeks before surgery
You likely can't join if
- Previously enrolled in this study (i.e. patient now at repeat encounter)
- AV-block II and III in patients without pacemaker
- Any other indication for dual antiplatelet therapy, i.e. recent stent implantation
- Debilitating stroke within 90 days before inclusion
- Previous intracranial bleeding
- Treatment with immunosuppressants (e.g. cyclosporine and tacrolimus)
See the full eligibility criteria
- Written informed consent
- Age ≥18 years
- Has undergone first time isolated CABG due to an episode of acute coronary syndrome (STEMI, NSTEMI, unstable angina) within 6 weeks before surgery
- Previously enrolled in this study (i.e. patient now at repeat encounter)
- AV-block II and III in patients without pacemaker
- Any other indication for dual antiplatelet therapy, i.e. recent stent implantation
- Debilitating stroke within 90 days before inclusion
- Previous intracranial bleeding
- Treatment with immunosuppressants (e.g. cyclosporine and tacrolimus)
- Treatment with strong CYP3A4-inhibitors (e.g. ketoconazole, clarithromycin, nefazodon, ritonavir or atazanavir)
- Any condition that in the opinion of the investigator may interfere with adherence to trial protocol
- Participation in any other clinical trial evaluating investigational products at the time for enrollment in this study
- Concomitant surgical procedure other than CABG
- Anticoagulant treatment after the operation (e.g. warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux)
- Discharge from the operating hospital to an ICU at another hospital
- Pregnancy or lactation
- Known intolerance or contraindication to ticagrelor or ASA
- Any disorder that may interfere with drug absorption
- Any condition other than coronary artery disease with a life expectancy <12 months
- Known chronic liver disease, renal disease requiring dialysis or bleeding disorder
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.